LY395756, an mGluR2 agonist and mGluR3 antagonist, enhances NMDA receptor expression and function in the normal adult rat prefrontal cortex, but fails to improve working memory and reverse MK801-induced working memory impairment

Experimental Neurology
Meng-Lin LiWen-Jun Gao

Abstract

Targeting group II metabotropic glutamate receptors (mGluR2/3) has been proposed to correct the dysfunctional glutamatergic system, particularly NMDA receptor (NMDAR) hypofunction, for treatment of schizophrenia. However, how activation of mGluR2/3 affects NMDAR function in adult animals remains elusive. Here we show the effects of LY395756 (LY39), a compound acting as both an mGluR2 agonist and mGluR3 antagonist, on the NMDAR expression and function of normal adult rat prefrontal cortex (PFC) as well as working memory function in the MK801 model of schizophrenia. We found that in vivo administration of LY39 significantly increased the total protein levels of NMDAR subunits and NR2B phosphorylationin the PFC, along with the amplitude of NMDAR-mediated miniature excitatory postsynaptic currents (mEPSC) in the prefrontal cortical neurons. Moreover, LY39 also significantly increased mTOR and pmTOR expression, but not ERK1/2, Akt, and GSK3β, suggesting an activation of mTOR signaling. Indeed, the mTOR inhibitor rapamycin, and actinomycin-D, a transcription inhibitor, blocked the enhanced effects of LY39 on NMDAR-mEPSCs. These results indicate that LY39 regulates NMDAR expression and function through unidentified mTOR-mediated prote...Continue Reading

References

Nov 14, 1997·International Clinical Psychopharmacology·D R Weinberger, B Gallhofer
Oct 26, 1999·Neuropharmacology·D D SchoeppJ A Monn
Jun 12, 2001·Current Opinion in Neurobiology·S Cull-CandyM Farrant
Jun 17, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Panayiotis TsokasRobert D Blitzer
Apr 20, 2006·Neurochemistry International·Ana María Sánchez-PérezVicente Felipo
Jul 19, 2006·Cell and Tissue Research·Francesco Ferraguti, Ryuichi Shigemoto
Dec 9, 2008·Trends in Pharmacological Sciences·P Jeffrey ConnCarrie K Jones
Mar 28, 2009·Schizophrenia Bulletin·Oliver D Howes, Shitij Kapur
Apr 8, 2010·European Journal of Pharmacology·Gerard J Marek
Jul 29, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Antonios Boultadakis, Nikolaos Pitsikas
Feb 18, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Dong XiWen-Jun Gao
May 6, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Laura CeolinDavid Lodge
Jan 21, 2012·Biochemical Society Transactions·Valentina IadevaiaChristopher G Proud
May 9, 2012·Neuropharmacology·Daniela DurandMercedes Lasaga
Feb 5, 2013·Scientific Reports·Catherine TrepanierJohn F MacDonald
Apr 2, 2013·Frontiers in Cellular Neuroscience·Melissa A Snyder, Wen-Jun Gao
Aug 1, 2013·Nature Reviews. Neuroscience·Cyril Hanus, Erin M Schuman
Feb 25, 2014·Neuron·Susanne Tom DieckErin M Schuman
Jul 6, 2014·The British Journal of Psychiatry : the Journal of Mental Science·Oliver D Howes, Shitij Kapur
Jul 23, 2014·Molecular Psychiatry·R S Kahn, I E Sommer
Aug 26, 2014·Seminars in Cell & Developmental Biology·Valentina IadevaiaChristopher G Proud

❮ Previous
Next ❯

Citations

Jul 3, 2019·Scientific Reports·Austin A Coley, Wen-Jun Gao
Apr 28, 2017·Molecular Brain·James MaksymetzP Jeffrey Conn
Oct 22, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jong-Hoon KimPaul Cumming

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here